Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

被引：4

作者：

Glas, A. ^{[1
]}

Peeters, J. ^{[1
]}

Yau, C. ^{[2
]}

Wolf, D. M. ^{[2
]}

Sanil, A. ^{[3
]}

Li, Y. ^{[4
]}

Severson, T. ^{[5
]}

Linn, S. ^{[5
]}

Buxton, M. ^{[2
]}

DeMichele, A. ^{[7
]}

Hylton, N. ^{[2
]}

Symmans, F. ^{[8
]}

Yee, D. ^{[9
]}

Paoloni, M. ^{[6
]}

Esserman, L. ^{[2
]}

Berry, D. ^{[3
]}

Rugo, H. ^{[2
]}

Olopade, O. ^{[10
]}

van 't Veer, L. J. ^{[2
]}

机构：

[1] Agendia, Amsterdam, Netherlands

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Berry Consultants LLC, San Francisco, CA USA

[4] Agendia, Irvine, CA USA

[5] NKI, Amsterdam, Netherlands

[6] QuantumLeap Healthcare, San Francisco, CA USA

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Minessota, Minneapolis, MN USA

[10] Univ Chicago, Chicago, IL 60637 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70658-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

532

引用

页码：173 / 173

页数：1

共 50 条

[21] Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard
Clark, Amy S.
Yau, Christina
Hylton, Nola
Li, Wen
Wolfe, Denise
Chien, A. Jo
Wallace, Anne M.
Forero-Torres, Andres
Stringer-Reasor, Erica
Nanda, Rita
Jaskowiak, Nora
Boughey, Judy
Haddad, Tufia
Han, Heather S.
Lee, Catherine
Albain, Kathy
Isaacs, Claudine
Elias, Anthony D.
Ellis, Erin D.
Shah, Payal
Lang, Julie E.
Lu, Janice
Tripathy, Debasish
Kemmer, Kathleen
Yee, Douglas
Haley, Barbara
Majure, Melanie
Roesch, Erin
Vaklavas, Christos
Ewing, Cheryl
Helsten, Teresa
Symmans, W. Fraser
Perlmutter, Jane
Rugo, Hope S.
Melisko, Michelle
Wilson, Amy
Singhrao, Ruby
van't Veer, Laura
De Michele, Angela
Asare, Smita
Berry, Don
Esserman, Laura J.
[J]. CANCER RESEARCH, 2019, 79 (13)
[22] Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial
Hylton, N.
Carey, L.
DeMichele, A.
Blume, J.
Broadwater, G.
Madhavan, S.
Rosen, M.
George, S.
Esserman, L.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S22 - S22
[23] Efficacy of pertuzumab/trastuzumab /paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Buxton, Meredith
DeMichele, Angela M.
Chia, Stephen
van't Veer, Laura
Chien, Jo
Wallace, Anne
Kaplan, Henry
Lang, Julie
Yee, Douglas
Isaacs, Claudine
Moulder, Stacy
Albain, Kathy
Boughey, Judy
Kemmer, Kathleen
Haley, Barbara
Minton, Susan
Forero, Andres
Nanda, Rita
Elias, Anthony
Korde, Larissa
Viscuzi, Rebecca
Rugo, Hope
Schwab, Richard
Symmans, Fraser
Paoloni, Melissa
Hylton, Nola
Hogarth, Michael
Lyandres, Julia
Perlmutter, Jane
Sanil, Ashish
Yau, Christina
Esserman, Laura
Berry, Don
[J]. CANCER RESEARCH, 2016, 76
[24] Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
Wen Li
David C. Newitt
Jessica Gibbs
Lisa J. Wilmes
Ella F. Jones
Vignesh A. Arasu
Fredrik Strand
Natsuko Onishi
Alex Anh-Tu Nguyen
John Kornak
Bonnie N. Joe
Elissa R. Price
Haydee Ojeda-Fournier
Mohammad Eghtedari
Kathryn W. Zamora
Stefanie A. Woodard
Heidi Umphrey
Wanda Bernreuter
Michael Nelson
An Ly Church
Patrick Bolan
Theresa Kuritza
Kathleen Ward
Kevin Morley
Dulcy Wolverton
Kelly Fountain
Dan Lopez-Paniagua
Lara Hardesty
Kathy Brandt
Elizabeth S. McDonald
Mark Rosen
Despina Kontos
Hiroyuki Abe
Deepa Sheth
Erin P. Crane
Charlotte Dillis
Pulin Sheth
Linda Hovanessian-Larsen
Dae Hee Bang
Bruce Porter
Karen Y. Oh
Neda Jafarian
Alina Tudorica
Bethany L. Niell
Jennifer Drukteinis
Mary S. Newell
Michael A. Cohen
Marina Giurescu
Elise Berman
Constance Lehman
[J]. npj Breast Cancer, 6
[25] Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
Li, Wen
Newitt, David C.
Gibbs, Jessica
Wilmes, Lisa J.
Jones, Ella F.
Arasu, Vignesh A.
Strand, Fredrik
Onishi, Natsuko
Nguyen, Alex Anh-Tu
Kornak, John
Joe, Bonnie N.
Price, Elissa R.
Ojeda-Fournier, Haydee
Eghtedari, Mohammad
Zamora, Kathryn W.
Woodard, Stefanie A.
Umphrey, Heidi
Bernreuter, Wanda
Nelson, Michael
Church, An Ly
Bolan, Patrick
Kuritza, Theresa
Ward, Kathleen
Morley, Kevin
Wolverton, Dulcy
Fountain, Kelly
Lopez-Paniagua, Dan
Hardesty, Lara
Brandt, Kathy
McDonald, Elizabeth S.
Rosen, Mark
Kontos, Despina
Abe, Hiroyuki
Sheth, Deepa
Crane, Erin P.
Dillis, Charlotte
Sheth, Pulin
Hovanessian-Larsen, Linda
Bang, Dae Hee
Porter, Bruce
Oh, Karen Y.
Jafarian, Neda
Tudorica, Alina
Niell, Bethany L.
Drukteinis, Jennifer
Newell, Mary S.
Cohen, Michael A.
Giurescu, Marina
Berman, Elise
Lehman, Constance
[J]. NPJ BREAST CANCER, 2020, 6 (01)
[26] Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Pusztai, Lajos
Han, Hyo S.
Yau, Christina
Wolf, Denise
Wallace, Anne M.
Shatsky, Rebecca
Helsten, Teresa
Boughey, Judy C.
Haddad, Tufia
Stringer-Reasor, Erica
Falkson, Carla
Chien, A. Jo
Mukhtar, Rita
Elias, Anthony
Virginia, Borges
Nanda, Rita
Yee, Douglas
Kalinsky, Kevin
Albain, Kathy S.
Muller, Aixa Soyano
Kemmer, Kathleen
Clark, Amy S.
Isaacs, Claudine
Thomas, Alexandra
Hylton, Nola
Symmans, W. Fraser
Perlmutter, Jane
Melisko, Michelle
Rugo, Hope S.
Schwab, Richard
Wilson, Amy
Singhrao, Ruby
Asare, Smita
van't Veer, Laura J.
DeMichele, Angela M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (16)
[27] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A.
Roesch, Erin
Yau, Christina
Lu, Ruixiao
Wolf, Denise
Samson, Susan
Stafford, Debra
Albain, Kathy S.
Isaacs, Claudine
Trivedi, Meghana
Yee, Douglas
Boughey, Judy
Thomas, Alexandra
Chien, A. Jo
Hylton, Nola
Li, Wen
DeMichele, Angela
Perlmutter, Jane
Symmans, W. Fraser
Hershman, Dawn L.
Melisko, Michelle
Veer, Laura J. van ' t
Wilson, Amy
Asare, Smita M.
Berry, Donald A.
Schwab, Richard
Rugo, Hope S.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2022, 82 (04)
[28] Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial
Sayaman, Rosalyn W.
Wolf, Denise M.
Yau, Christina
Wulfkuhle, Julie
Petricoin, Emanuel
Brown-Swigart, Lamorna
Asare, Smita M.
Hirst, Gillian L.
Sit, Laura
O'Grady, Nicholas
Hedistian, Diane
Esserman, Laura J.
LaBarge, Mark A.
van't Veer, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[29] Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL
Magbanua, Mark Jesus M.
Li, Wen
Wolf, Denise M.
Yau, Christina
Hirst, Gillian L.
Brown-Swigart, Lamorna
Chien, A. Jo
Delson, Amy L.
Gibbs, Jessica
Aleshin, Alexey
Zimmerman, Bernhard
Esserman, Laura
Hylton, Nola
van't Veer, Laura
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (11) : 59 - 60
[30] DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.
van't Veer, Laura
Esserman, Laura
Sanil, Ashish
Glas, Annuska
Severson, Tessa
Linn, Sabine C.
Swigart, Lamorna Brown
Hirst, Gillian
Olopade, Olufunmilayo I.
Rugo, Hope S.
Berry, Don
Wolf, Denise M.
Yau, Christina
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →